These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26137961)

  • 1. CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol.
    Ghazavi F; Clappier E; Lammens T; Suciu S; Caye A; Zegrari S; Bakkus M; Grardel N; Benoit Y; Bertrand Y; Minckes O; Costa V; Ferster A; Mazingue F; Plat G; Plouvier E; Poirée M; Uyttebroeck A; van der Werff-Ten Bosch J; Yakouben K; Helsmoortel H; Meul M; Van Roy N; Philippé J; Speleman F; Cavé H; Van Vlierberghe P; De Moerloose B
    Haematologica; 2015 Oct; 100(10):1311-9. PubMed ID: 26137961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detailed gene dose analysis reveals recurrent focal gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia.
    Ivanov Öfverholm I; Tran AN; Olsson L; Zachariadis V; Heyman M; Rudd E; Syk Lundberg E; Nordenskjöld M; Johansson B; Nordgren A; Barbany G
    Leuk Lymphoma; 2016 Sep; 57(9):2161-70. PubMed ID: 27090575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.
    Ribera J; Morgades M; Zamora L; Montesinos P; Gómez-Seguí I; Pratcorona M; Sarrà J; Guàrdia R; Nomdedeu J; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; González-Campos J; Barba P; Escoda L; Genescà E; Solé F; Millá F; Feliu E; Ribera JM;
    Cancer; 2015 Nov; 121(21):3809-17. PubMed ID: 26194343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
    Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
    Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
    Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
    Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.
    Krentz S; Hof J; Mendioroz A; Vaggopoulou R; Dörge P; Lottaz C; Engelmann JC; Groeneveld TW; Körner G; Seeger K; Hagemeier C; Henze G; Eckert C; von Stackelberg A; Kirschner-Schwabe R
    Leukemia; 2013 Feb; 27(2):295-304. PubMed ID: 22699455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.
    Clappier E; Grardel N; Bakkus M; Rapion J; De Moerloose B; Kastner P; Caye A; Vivent J; Costa V; Ferster A; Lutz P; Mazingue F; Millot F; Plantaz D; Plat G; Plouvier E; Poirée M; Sirvent N; Uyttebroeck A; Yakouben K; Girard S; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Cavé H;
    Leukemia; 2015 Nov; 29(11):2154-61. PubMed ID: 26050650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
    Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
    Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
    Kuiper RP; Waanders E; van der Velden VH; van Reijmersdal SV; Venkatachalam R; Scheijen B; Sonneveld E; van Dongen JJ; Veerman AJ; van Leeuwen FN; van Kessel AG; Hoogerbrugge PM
    Leukemia; 2010 Jul; 24(7):1258-64. PubMed ID: 20445578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preserved global histone H4 acetylation linked to ETV6-RUNX1 fusion and PAX5 deletions is associated with favorable outcome in pediatric B-cell progenitor acute lymphoblastic leukemia.
    Janczar K; Janczar S; Pastorczak A; Mycko K; Paige AJ; Zalewska-Szewczyk B; Wagrowska-Danilewicz M; Danilewicz M; Mlynarski W
    Leuk Res; 2015 Dec; 39(12):1455-61. PubMed ID: 26520622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
    Usami I; Imamura T; Takahashi Y; Suenobu SI; Hasegawa D; Hashii Y; Deguchi T; Hori T; Shimada A; Kato K; Ito E; Moriya-Saito A; Kawasaki H; Hori H; Yumura-Yagi K; Hara J; Sato A; Horibe K;
    Int J Hematol; 2019 Apr; 109(4):477-482. PubMed ID: 30689137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.
    Clappier E; Auclerc MF; Rapion J; Bakkus M; Caye A; Khemiri A; Giroux C; Hernandez L; Kabongo E; Savola S; Leblanc T; Yakouben K; Plat G; Costa V; Ferster A; Girard S; Fenneteau O; Cayuela JM; Sigaux F; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Soulier J; Cavé H
    Leukemia; 2014 Jan; 28(1):70-7. PubMed ID: 24064621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features.
    Schwab CJ; Chilton L; Morrison H; Jones L; Al-Shehhi H; Erhorn A; Russell LJ; Moorman AV; Harrison CJ
    Haematologica; 2013 Jul; 98(7):1081-8. PubMed ID: 23508010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols.
    Ofverholm I; Tran AN; Heyman M; Zachariadis V; Nordenskjöld M; Nordgren A; Barbany G
    Leukemia; 2013 Sep; 27(9):1936-9. PubMed ID: 23538749
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.
    Boer JM; van der Veer A; Rizopoulos D; Fiocco M; Sonneveld E; de Groot-Kruseman HA; Kuiper RP; Hoogerbrugge P; Horstmann M; Zaliova M; Palmi C; Trka J; Fronkova E; Emerenciano M; do Socorro Pombo-de-Oliveira M; Mlynarski W; Szczepanski T; Nebral K; Attarbaschi A; Venn N; Sutton R; Schwab CJ; Enshaei A; Vora A; Stanulla M; Schrappe M; Cazzaniga G; Conter V; Zimmermann M; Moorman AV; Pieters R; den Boer ML
    Leukemia; 2016 Jan; 30(1):32-8. PubMed ID: 26202931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?
    Palmi C; Valsecchi MG; Longinotti G; Silvestri D; Carrino V; Conter V; Basso G; Biondi A; Kronnie GT; Cazzaniga G
    Haematologica; 2013 Aug; 98(8):1226-31. PubMed ID: 23585525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of copy number abnormalities in common genes associated with B-cell precursor acute lymphoblastic leukemia cytogenetic subtypes in Brazilian children.
    Barbosa TC; Terra-Granado E; Quezado Magalhães IM; Neves GR; Gadelha A; Guedes Filho GE; Souza MS; Melaragno R; Emerenciano M; Pombo-de-Oliveira MS
    Cancer Genet; 2015 Oct; 208(10):492-501. PubMed ID: 26277549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011.
    Olsson L; Castor A; Behrendtz M; Biloglav A; Forestier E; Paulsson K; Johansson B
    Leukemia; 2014 Feb; 28(2):302-10. PubMed ID: 23823658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
    Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
    Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interphase fluorescent in situ hybridization deletion analysis of the 9p21 region and prognosis in childhood acute lymphoblastic leukaemia (ALL): results from a prospective analysis of 519 Nordic patients treated according to the NOPHO-ALL 2000 protocol.
    Kuchinskaya E; Heyman M; Nordgren A; Söderhäll S; Forestier E; Wehner P; Vettenranta K; Jonsson O; Wesenberg F; Sahlén S; Nordenskjöld M; Blennow E
    Br J Haematol; 2011 Mar; 152(5):615-22. PubMed ID: 21241277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.